Galectin Therapeutics Inc.
GALT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $37 | $32 | $32 | $24 |
| G&A Expenses | $0 | $6 | $0 | $0 |
| SG&A Expenses | $6 | $6 | $7 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $42 | $38 | $38 | $30 |
| Operating Income | -$42 | -$38 | -$38 | -$30 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$5 | -$3 | -$0 | -$0 |
| Pre-Tax Income | -$47 | -$41 | -$39 | -$31 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$47 | -$41 | -$39 | -$31 |
| % Margin | – | – | – | – |
| EPS | -0.76 | -0.74 | -0.65 | -0.52 |
| % Growth | -2.7% | -13.8% | -25% | – |
| EPS Diluted | -0.76 | -0.74 | -0.65 | -0.52 |
| Weighted Avg Shares Out | 62 | 60 | 59 | 59 |
| Weighted Avg Shares Out Dil | 62 | 60 | 59 | 59 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $6 | $3 | $1 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$41 | -$38 | -$38 | -$30 |
| % Margin | – | – | – | – |